---
title: "Analyst Maintains Hold on GE HealthCare as Innovation Upside Remains Back-End Loaded Amid Near-Term Macro and Execution Risks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292118561.md"
description: "BMO Capital initiated a Hold rating on GE HealthCare (GEHC), citing balanced risk and reward. While long-term innovation drivers like Flyrcado are promising, their impact is delayed until 2027-2028, making 2026 a transition year with limited upside. Near-term risks include macro pressures, China weakness, and execution challenges. Citi also maintained a Hold rating with a $69 price target."
datetime: "2026-07-08T20:35:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292118561.md)
  - [en](https://longbridge.com/en/news/292118561.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292118561.md)
---

# Analyst Maintains Hold on GE HealthCare as Innovation Upside Remains Back-End Loaded Amid Near-Term Macro and Execution Risks

, an analyst from BMO Capital, has initiated a new Hold rating on GE Healthcare Technologies Inc (GEHC).

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

analyst has given his Hold rating due to a combination of factors, balancing GEHC’s strong innovation pipeline against near-term execution and macro risks. While Flyrcado and Photonova Spectra represent meaningful long-term growth drivers, their financial impact is back-end loaded into 2027–2028, leaving 2026 as more of a transition year with limited visible upside.

At the same time, repeated macro-driven guidance cuts, unresolved weakness in China, and reliance on a second-half recovery that must juggle backlog conversion, inflation mitigation, and pricing actions create a “show-me” setup. Given this backdrop and recent earnings-volatility, the analyst views risk and reward as roughly in equilibrium at the current valuation and prefers to see several quarters of consistent delivery before considering a more constructive rating.

In another report released today, Citi also maintained a Hold rating on the stock with a $69.00 price target.

### Related Stocks

- [GEHC.US](https://longbridge.com/en/quote/GEHC.US.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Are Wall Street Analysts Predicting GE HealthCare Stock Will Climb or Sink?](https://longbridge.com/en/news/295387657.md)
- [Trian Fund Management Lp Raises Share Stake In Ge Healthcare Technologies, Cuts In Invesco Ltd](https://longbridge.com/en/news/295712326.md)
- [Cardano Risk Management B.V. Takes $105.17 Million Position in GE Vernova Inc. $GEV](https://longbridge.com/en/news/295318838.md)
- [General Electric (GE) On GE Vernova Miss, Is The Stock Fully Valued](https://longbridge.com/en/news/295313532.md)
- [Worth Asset Management LLC Sells 1,691 Shares of GE Vernova Inc. $GEV](https://longbridge.com/en/news/295298981.md)